Recently, it has been reported that a variety of myositis-specific autoantibodies (MSAs) associated with tumors has been found in patients with dermatomyositis, including transcriptional intermediary factor 1-gamma (TIF-1γ), nuclear matrix protein (NXP-2), anti-small ubiquitin-like modifier activating enzyme (SAE), anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), etc (Trallero-Araguas et al., 2010). Here, TRIM33 is linked to dermatomyositis.